CCFM
MLTX icon

Cohen & Co Financial Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cohen & Co Financial Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$989K – 84
2021
Q4 		$989K Buy
+100,000
New +$994K 0.66% 64

Other funds holding MLTX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Cohen & Co Financial Management's MLTX Position: Q1 2022 in Review

Cohen & Co Financial Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2022, closing a stake of 100,000 shares — an estimated $989K sold.

Cohen & Co Financial Management first reported a position in MLTX in Q4 2021 and held it in 1 quarter. The position peaked at $989K in Q4 2021. 27 funds tracked by Wall St. Rank hold MLTX as of Q1 2022.

  • Cohen & Co Financial Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Cohen & Co Financial Management sold 100,000 MoonLake Immunotherapeutics shares in Q1 2022, an estimated $989K.
  • Cohen & Co Financial Management first reported a position in MoonLake Immunotherapeutics in Q4 2021 and held it in 1 quarter.
  • Cohen & Co Financial Management's MoonLake Immunotherapeutics position peaked at $989K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2022.

Based on Cohen & Co Financial Management's 13F filing for Q1 2022, filed 16 May 2022.